Welcome to Tradeoff Land: The Carnival of Compromise!

References: 1. Kestenbaum B, Sampson JN, Rudser KD, et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol. 2005;16(2):520-528. Doi:10.1681/ASN.2004070602 2. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) [published correction appears in Kidney Int Suppl (2011). 2017 Dec;7(3):e1. doi: 10.1016/j.kisu.2017.10.001]. Kidney Int Suppl (2011). 2017;7(1):1-59. doi:10.1016/j.kisu.2017.04.001 3. US-DOPPS Practice Monitor, May 2021; http://www.dopps.org/DPM 4. Floege J. Phosphate binders in chronic kidney disease: an updated narrative review of recent data. J Nephrol. 2020 Jun;33(3):497-508. 5. Huml AM, Sullivan CM, Leon JB, et al. The adequacy of phosphorus binder prescriptions among American hemodialysis patients. Ren Fail. 2012;34(10):1258-63 6. Chiu YW, Teitelbaum I, Misra M, et al. Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients. Clin J Am Soc Nephrol. 2009 Jun;4(6):1089-96. 7. Data on file. Unicycive Therapeutics, Inc; 2024. 8. Umeukeje EM, Mixon AS, Cavanaugh KL. Phosphate-control adherence in hemodialysis patients: current perspectives. Patient Prefer Adherence. 2018;12:1175-1191.

Hyperphosphatemia is a silent killer that affects more than 80% of patients on dialysis and has been directly linked to increased morbidity and mortality.¹

Clinical practice guidelines recommend lowering elevated phosphate levels toward the normal range of 2.5 - 4.5 mg/dL.²

Despite the availability of 7 FDA-approved phosphate-lowering therapies, hyperphosphatemia remains uncontrolled in an estimated 75% of U.S. dialysis patients.³

Hyperphosphatemia is a silent killer that affects more than 80% of patients on dialysis and has been directly linked to increased morbidity and mortality.¹

Clinical practice guidelines recommend lowering elevated phosphate levels toward the normal range of 2.5 - 4.5 mg/dL.²

Despite the availability of 7 FDA-approved phosphate-lowering therapies, hyperphosphatemia remains uncontrolled in an estimated 75% of U.S. dialysis patients.³

The current state of hyperphosphatemia therapy forces you and your patients to choose between inadequate options.

No phosphate-lowering therapy to date fully meets the three critical requirements for successful treatment: potency , low pill burden, and palatability.⁴

The current state of hyperphosphatemia therapy forces you and your patients to choose between inadequate options.

No phosphate-lowering therapy to date has met three critical requirements for successful treatment: potency, low pill burden, and palatability.⁴

Common phosphate binders have insufficient binding capacity for typical phosphorous intake for hyperphosphatemia patients.⁵

Insufficient binding capacity leads to high pill burden.

The median daily pill burden in dialysis patients is 19 pills–one of the highest reported to date in any chronic disease state.³

Half of this pill burden is from phosphate binders.⁶

Chewable binders are not preferred by most patients due to their chalkiness and metallic taste.⁷

Other binders are hard to swallow due to their large size.⁵

The unpalatable nature of these treatments may deter patient adherence.

Common phosphate binders have insufficient binding capacity for typical phosphorous intake for hyperphosphatemia patients.⁵

Insufficient binding capacity leads to high pill burden. The median daily pill burden in dialysis patients is 19 pills–one of the highest reported to date in any chronic disease state.³ Half of this pill burden is from phosphate binders.⁶

Chewable binders are not preferred by most patients due to their chalkiness and metallic taste.⁷Other binders are hard to swallow due to their large size.⁵ The unpalatable nature of these treatments may deter patient adherence.

With a tradeoff always present, patients remain unable to consistently achieve guideline-established target serum phosphorous levels due to non-adherence.⁸

Ouch!

With a tradeoff always present, patients remain unable to consistently achieve guideline-established target serum phosphorous levels due to non-adherence.⁸

Ouch!

By enhancing potency through its patented nanoparticle technology, Unicycive aspires to finally develop a solution that satisfies all three Ps.

By enhancing potency through its patented nanoparticle technology, Unicycive aspires to finally develop a solution that satisfies all three Ps‍.

Hyperphosphatemia is a silent killer that affects more than 80% of patients on dialysis and has been directly linked to increased morbidity and mortality.1

Clinical practice guidelines recommend lowering elevated phosphate levels toward the normal range of 2.5 - 4.5 mg/dL.2

Despite the availability of 7 FDA-approved phosphate-lowering therapies, hyperphosphatemia remains uncontrolled in an estimated 75% of U.S. dialysis patients.3

Hyperphosphatemia is a silent killer that affects more than 80% of patients on dialysis and has been directly linked to increased morbidity and mortality.1

Clinical practice guidelines recommend lowering elevated phosphate levels toward the normal range of 2.5 - 4.5 mg/dL.2

Despite the availability of 7 FDA-approved phosphate-lowering therapies, hyperphosphatemia remains uncontrolled in an estimated 75% of U.S. dialysis patients.3

The current state of hyperphosphatemia therapy forces you and your patients to choose between inadequate options. No phosphate-lowering therapy to date fully meets the three critical requirements for successful treatment: potency , low pill burden, and palatability.4

The current state of hyperphosphatemia therapy forces you and your patients to choose between inadequate options.No phosphate-lowering therapy to date has met three critical requirements for successful treatment: potency, low pill burden, and palatability.4

Common phosphate binders have insufficient binding capacity for typical phosphorous intake for hyperphosphatemia patients.5

Insufficient binding capacity leads to high pill burden. The median daily pill burden in dialysis patients is 19 pills–one of the highest reported to date in any chronic disease state.3 Half of this pill burden is from phosphate binders.6

Chewable binders are not preferred by most patients due to their chalkiness and metallic taste.7 Other binders are hard to swallow due to their large size.5 The unpalatable nature of these treatments may deter patient adherence.

Common phosphate binders have insufficient binding capacity for typical phosphorous intake for hyperphosphatemia patients.5

Insufficient binding capacity leads to high pill burden. The median daily pill burden in dialysis patients is 19 pills–one of the highest reported to date in any chronic disease state.3 Half of this pill burden is from phosphate binders.6

Chewable binders are not preferred by most patients due to their chalkiness and metallic taste.7 Other binders are hard to swallow due to their large size.5 The unpalatable nature of these treatments may deter patient adherence.

With a tradeoff always present, patients remain unable to consistently achieve guideline-established target serum phosphorous levels due to non-adherence.8 Ouch!

With a tradeoff always present, patients remain unable to consistently achieve guideline-established target serum phosphorous levels due to non-adherence.8 Ouch!

By enhancing potency through its patented nanoparticle technology, Unicycive aspires to finally develop a solution that satisfies all three Ps.

By enhancing potency through its patented nanoparticle technology, Unicycive aspires to finally develop a solution that satisfies all three Ps‍.

Hyperphosphatemia is a silent killer that affects more than 80% of patients on dialysis and has been directly linked to increased morbidity and mortality.¹

Clinical practice guidelines recommend lowering elevated phosphate levels toward the normal range of 2.5 - 4.5 mg/dL.²

Despite the availability of 7 FDA-approved phosphate-lowering therapies, hyperphosphatemia remains uncontrolled in an estimated 75% of U.S. dialysis patients.³

Hyperphosphatemia is a silent killer that affects more than 80% of patients on dialysis and has been directly linked to increased morbidity and mortality.¹

Clinical practice guidelines recommend lowering elevated phosphate levels toward the normal range of 2.5 - 4.5 mg/dL.²

Despite the availability of 7 FDA-approved phosphate-lowering therapies, hyperphosphatemia remains uncontrolled in an estimated 75% of U.S. dialysis patients.³

The current state of hyperphosphatemia therapy forces you and your patients to choose between inadequate options.

No phosphate-lowering therapy to date fully meets the three critical requirements for successful treatment: potency , low pill burden, and palatability.⁴

The current state of hyperphosphatemia therapy forces you and your patients to choose between inadequate options.

No phosphate-lowering therapy to date has met three critical requirements for successful treatment: potency, low pill burden, and palatability.⁴

Common phosphate binders have insufficient binding capacity for typical phosphorous intake for hyperphosphatemia patients.⁵

Insufficient binding capacity leads to high pill burden.

The median daily pill burden in dialysis patients is 19 pills–one of the highest reported to date in any chronic disease state.³

Half of this pill burden is from phosphate binders.⁶

Chewable binders are not preferred by most patients due to their chalkiness and metallic taste.⁷

Other binders are hard to swallow due to their large size.⁵

The unpalatable nature of these treatments may deter patient adherence.

Common phosphate binders have insufficient binding capacity for typical phosphorous intake for hyperphosphatemia patients.⁵

Insufficient binding capacity leads to high pill burden. The median daily pill burden in dialysis patients is 19 pills–one of the highest reported to date in any chronic disease state.³ Half of this pill burden is from phosphate binders.⁶

Chewable binders are not preferred by most patients due to their chalkiness and metallic taste.⁷Other binders are hard to swallow due to their large size.⁵ The unpalatable nature of these treatments may deter patient adherence.

With a tradeoff always present, patients remain unable to consistently achieve guideline-established target serum phosphorous levels due to non-adherence.⁸

Ouch!

With a tradeoff always present, patients remain unable to consistently achieve guideline-established target serum phosphorous levels due to non-adherence.⁸

Ouch!